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Abstract. Purpose: To evaluate the diagnostic impact and
clinical significance of FDG-avid bone lesions detected by
FDG-PET/CT in patients with lymphoma.
Methods: The study population comprised 50 consecutive
patients (mean age 41.7±15.5 years; 27 female, 23 male; 41
staging, 9 restaging) with Hodgkin’s disease (n=22) or
aggressive non-Hodgkin’s lymphoma (n=28) in whom
FDG-avid bone lesions were detected by FDG-PET/CT.
All patients had either direct biopsy of the FDG-avid bone
lesion (n=18), standard bone marrow biopsy at the iliac crest
(BMB; n=43) or both procedures (n=11). In 15 patients,
additional MRI of the bone lesions was performed. All
patients underwent FDG-PET/CT after the end of treatment.
All CT images of FDG-PET/CT scans were analysed
independently regarding morphological osseous changes
and compared with FDG-PET results.
Results: In the 50 patients, 193 FDG-avid lesions were found
by PET/CT. The mean standardised uptake value was 6.26
(±3.22). All direct bone biopsies (n=18) of the FDG-avid
lesions proved the presence of lymphomatous infiltration.
BMB (n=43) was positive in 12 patients (27.9%). In CT, 32
of 193 (16.6%) lesions were detected without the PET
information. No additional morphological bone infiltration
was detected on CT compared with FDG-PET. All morpho-
logical bone alterations onCTscans persisted after the end of
therapy. Additional PET/CT information regarding uni- or
multifocal bone involvement resulted in lymphoma upstag-
ing in 21 (42%) patients compared with the combined infor-
mation provided by CT and BMB.
Conclusion: In patients with FDG-avid bone lesions, FDG-
PET is superior to CTalone or in combination with unilateral
BMB in detecting bone marrow involvement, leading to
upstaging in a relevant proportion of patients.
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Introduction
Positron emission tomography (PET) using 18F-fluoro-
deoxyglucose (FDG) has been used successfully for
staging and follow-up examinations in patients with ag-
gressive non-Hodgkin’s lymphoma (NHL) and Hodgkin’s
disease (HD) [1–3]. Studies have proven that FDG-PET is
more accurate than contrast-enhanced computed tomogra-
phy (CT) in the staging and restaging of malignant
lymphoma [1]. Few data are available regarding the
diagnostic impact of FDG-PET in patients with malignant
lymphoma and bone marrow involvement [4–6]. Data from
patients with primary bone lymphoma suggest that FDG-
PET scanning adds important information relevant to
management decisions [7, 8].
It is still under discussion whether FDG-PET can reduce
significantly the need for staging bone marrow biopsies
(BMB) at the iliac crest [4, 5]. However, in a recent meta-
analysis, a good, but not excellent correlation was demon-
strated between FDG-PET and BMB in the detection of
bone marrow involvement in the staging of patients with
malignant lymphoma [6].
BMB is an invasive diagnostic procedure which allows
the analysis of only a very limited area, and uni- or
multifocal bone marrow involvement at locations other
than the iliac crest can consequently be missed. In HD and
NHL, unilateral iliac crest biopsy is false negative
compared with bilateral iliac biopsy in up to 80% of the
patients [9]. In view of these data, BMB cannot be regarded
as a histological gold standard for bone involvement or
bone marrow infiltration. Obviously, it is essential to have a
routine diagnostic procedure, possibly consisting of a
multi-step approach, to reliably assess bone marrow
infiltration in patients with HD or NHL.
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The purpose of this study was to evaluate the diagnostic
value and clinical significance of FDG-avid bone lesions
diagnosed by FDG-PET/CT as the first step in staging of
patients with lymphoma.
Materials and methods
Patients
All patients with HD or aggressive NHL who presented between
January 2003 and November 2005 and who had uni- or multifocal
FDG-avid lesions in the bone were analysed (mean age 41.69±15.53
years; 27 female, 23 male; 41 primary staging, 9 staging of recurrent
disease). Patients had either direct bone marrow biopsy of the FDG-
avid lesion (n=18), standard biopsy at the iliac crest (n=43) or both
(n=11). In 15 patients, magnetic resonance imaging (MRI) of the
bone lesions was additionally performed. All patients underwent
FDG-PET/CT after the end of treatment. Patient characteristics are
listed in Tables 1, 2 and 3.
All FDG-PET images and CT scans were analysed separately by
one double board-certified nuclear medicine physician and radiologist
and one board-certified radiologist with 3 years’ experience in nuclear
medicine. Suspected focal bone marrow infiltration by FDG-PETwas
compared with morphological changes in the corresponding CT scan.
Table 1. Patient characteristics (total group)
Characteristics No. of patients
Total no of patients 50
Sex
Male 22
Female 28
Age, years
Mean±SD 41.7 years (±15.5)
Range 14–75 years
Histology
HD 22
NHL 28
Modality
Initial staging 41
Restaging 9
Table 2. Characteristics, histology and treatment of 22 HD patients
with bone involvement
No. Sex Age
(years)
Histology Treatment
1 m 23 HD, mixed cell ABVD
2 f 34 HD, nodular sclerosis CBV
3 f 31 HD, nodular sclerosis BEACOPP
4 m 47 HD, nodular sclerosis EPOCH/CBV/radiation
5 m 31 HD, nodular sclerosis ABVD
6 m 19 HD, nodular sclerosis ABVD
7 f 37 HD, nodular sclerosis ABVD
8 m 33 HD, nodular sclerosis ABVD/radiation
9 m 14 HD, nodular sclerosis ABVD
10 m 23 HD, nodular sclerosis ABVD/radiation
11 m 17 HD, nodular sclerosis ABVD
12 f 20 HD, nodular sclerosis ABVD/radiation
13 f 21 HD, nodular sclerosis ABVD
14 f 62 HD, nodular sclerosis ABVD/radiation
15 m 31 HD, nodular sclerosis ABVD
16 f 28 HD, nodular sclerosis ABVD/radiation
17 m 19 HD, nodular sclerosis CBV
18 f 28 HD, nodular sclerosis ABVD/radiation
19 f 27 HD, nodular sclerosis ABVD
20 f 35 HD, nodular sclerosis ABVD
21 f 57 HD, nodular sclerosis ABVD
22 m 24 HD, nodular sclerosis ABVD
m Male; f female; ABVD adriamycin, bleomycin, vinblastin
and dacarbazine; CBV cyclophosphamide, carmustine and
etoposide; EPOCH etoposide, prednisone, Oncovin,
cyclophosphamide and doxorubicin hydrochloride; BEACOPP
bleomycin, etoposide, adriamycin, cyclophosphamide, Oncovin,
procarbazine and prednisone
Table 3. Characteristics, histology and treatment of 28 NHL patients
with bone involvement
No. Sex Age
(years)
Histology Treatment
1 m 50 Anaplastic T cell lymphoma CHOP
2 m 40 Diffuse large B cell lymphoma R-EPOCH
3 m 59 Diffuse large B cell lymphoma R-CHOP
4 m 34 Diffuse large B cell lymphoma R-EPOCH
5 m 30 Diffuse large B cell lymphoma R-CHOP
6 m 56 Diffuse large B cell lymphoma R-EPOCH
7 m 68 Diffuse large B cell lymphoma R-CHOP
8 m 71 Diffuse large B cell lymphoma R-CHOP
9 f 62 Diffuse large B cell lymphoma R-CHOP
10 f 36 Diffuse large B cell lymphoma R-CHOP
11 f 70 Diffuse large B cell lymphoma CHOP
12 m 33 Diffuse large B cell lymphoma R-CHOP
13 m 62 Primary bone lymphoma Radiation
14 m 69 Follicular lymphoma, grade III R-CHOP
15 f 75 Follicular lymphoma, grade III R-CHOP
16 f 71 Follicular lymphoma, grade II R-CHOP
17 f 41 Primary B cell bone lymphoma Radiation
18 m 39 EBV-associated B lymphoma R
19 f 36 Diffuse large B cell lymphoma R-CHOP
20 f 27 Diffuse large B cell lymphoma R-CHOP
21 f 70 Diffuse large B cell lymphoma R-CHOP
22 f 24 Anaplastic T cell lymphoma CHOP
23 f 66 Follicular lymphoma, grade III R-CHOP
24 f 28 Diffuse large B cell lymphoma R-CHOP
25 f 47 Lymphoblastic B-NHL R-
HyperCVAD
26 f 59 Diffuse large B cell lymphoma R-CHOP
27 f 57 Transformed follicular
lymphoma, grade III
R-EPOCH
28 f 39 Follicular lymphoma, grade III R-CHOP
m Male; f female; CHOP cyclophosphamide, hydroxydaunorubicin,
vincristine and prednisone; R rituximab; EPOCH etoposide,
prednisone, Oncovin, cyclophosphamide and doxorubicin
hydrochloride; HyperCVAD hyperfractionated cyclophosphamide,
vincristine, doxorubicin and dexamethasone
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The FDG-PET/CT images of all patients were reviewed in accordance
with the ethical guidelines of the hospital institutional review board
after signed written informed consent had been obtained.
Imaging
All data were acquired on a combined PET/CT in-line system
(Discovery LS, GE Healthcare, Waukesha, WI, USA). This dedicated
system integrates a GE Advance NXi PET scanner with a multislice
helical CT (LightSpeed plus) and permits the acquisition of co-
registered CT and PET images in one session.
Patients fasted for at least 4 h prior to scanning, which started 40–
60 min after the injection of a standard dose of 370 MBq of FDG. In
addition, oral CT contrast agent (Micropaque Scanner, Guerbet AG,
Aulnay-sous-bois, France) was given starting 15 min before the
injection of FDG. Patients were examined in the supine position. No
intravenous contrast agent was given. Initially, the CT scan was
acquired starting at the level of the head using the following
parameters: 80 mA, 140 kV, 0.5 s/tube rotation, slice thickness
4.25 mm, scan length 867 mm, data acquisition time 22.5 s. The CT
Fig. 1. PET/CT images for
restaging in a 32-year-old
woman with recurrence of HD.
a Coronal maximum intensity
projection image showing in-
tense FDG uptake in cervical
(upper arrow), mediastinal
(lower arrow), axillary (arrow
at the left axilla) and iliac
(lowest arrow) lymph nodes as
well as an FDG-avid lesion in
the spleen (short arrow). There
are multiple lesions with FDG
uptake in the bones (arrow-
heads; left humerus, pelvis, both
proximal femora). b Bone win-
dow of the axial CT image at the
level of the upper thorax shows
enlarged axillary lymph nodes
(arrow) but normal bone struc-
ture of the scapula (arrow-
heads). c, d Corresponding axial
PET image (c) and fused PET/
CT image (d) demonstrate
intense FDG uptake in enlarged
axillary lymph nodes
(arrow) and the scapula
(arrowheads). BMB was nega-
tive in this patient
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scan was acquired in breath hold in the normal expiration position
and covered from the head to the pelvic floor.
Immediately following the CT acquisition, a PET emission scan
was acquired using an acquisition time of 3 min for the emission scan
per bed position with a one-slice overlap. Six to seven bed positions
from the pelvic floor to the head resulted in an acquisition time of
approximately 18–21 min. The CT data were used for attenuation
correction and images were reconstructed using a standard iterative
algorithm (OSEM). The acquired images were viewed with a
software providing multiplanar reformatted images of PET, CT and
fused data with linked cursors (Xeleris workstation, version 1.0728;
GE Healthcare, Waukesha, USA).
Analysis
As indicated above, PET/CT images were reviewed separately by
one double board-certified nuclear medicine physician and radio-
logist and one board-certified radiologist with 3 years’ experience in
nuclear medicine for the presence of FDG-avid lesions located in the
bone. All detected FDG-avid lesions in the bone were objectively
analysed by measurement of the calculated standardised uptake value
(SUV).
To assess the impact of PET/CT on staging of patients
with lymphoma, all patients had either BMB at the iliac crest or a
PET/CT-guided or open biopsy of the FDG-avid lesion or both
procedures.
To assess the value of the CT scans, the presence of osteoscle-
rotic, osteolytic or mixed bone changes was evaluated on the bone
window of the CT images. Additionally, CT images were analysed
for further osseous lesions without FDG uptake. To assess the impact
of PET/CT on staging of patients with lymphoma, all information,
including histology, BMB and non-contrast-enhanced CT informa-
tion, was subsumed for staging and compared with the same
information combined with FDG-PET/CT results. This method
permitted assessment of the additional benefit of functional PET
information without the bias of possible wrong localisation of FDG-
avid lesions.
Results
In 50 consecutive patients, 193 skeletal FDG-avid lesions
were found on PET/CT. No additional osseous, FDG-
inactive lesion suspicious for bone involvement was found
on any CT image. Localisation of the FDG-avid lesions
was as follows: spine, n=70; pelvis, n=57; femur, n=27;
humerus, n=11; ribs, n=7; sternum, n=7; scapula, n=7
(Fig. 1); clavicle, n=5; mandible, n=2. Mean SUV of the
bone lesions was 6.26±3.22.
Of the 50 patients, 18 (36%) had direct biopsy of the
FDG-avid lesion in the bone. All direct bone biopsies of the
FDG-avid lesions revealed lymphomatous infiltration. In
11 of these patients, BMB was also performed, and was
negative in seven (63.6%). In the other seven patients, only
a direct osseous biopsy of the FDG-avid lesion without
BMB was performed. In three of the aforementioned 18
patients, MRI was performed and revealed bone marrow
alterations.
Table 4. Number of bone lesions, biopsy results and staging with PET/CT and CT alone in 22 HD patients
No. Lesions on
PET/CTa
Lesions
on CTa
Iliac crest biopsy Direct biopsy Site of biopsy MRI Staging w/o
FDG-PET
Staging with
FDG-PET
1 2 0 Negative Not performed Not performed III IV
2 9 0 Positive Positive Femoral neck Not performed IV IV
3 10 0 Negative Not performed Positive IIIS IV
4 1 1 Positive Positive Sternum Not performed IV IV
5 10 0 Negative Not performed Not performed IIIS IV
6 2 2 Negative Not performed Not performed IV IV
7 3 2 Negative Not performed Not performed IV IV
8 1 1 Negative Not performed Not performed IV IV
9 4 0 Negative Not performed Positive II IV
10 1 1 Negative Not performed Positive IV IV
11 1 0 Positive Not performed Positive III IV
12 1 1 Negative Not performed Not performed IV IV
13 3 1 Negative Positive Positive IV IV
14 1 0 Negative Positive Trochanter Not performed I IV
15 1 1 Not performed Positive Ileum Not performed IV IV
16 1 0 Negative Not performed Positive II IV
17 1 0 Negative Not performed Not performed III IV
18 1 0 Negative Not performed Positive II IV
19 3 0 Negative Not performed Positive III IV
20 3 0 Negative Not performed Not performed IV IV
21 4 0 Negative Not performed Not performed III IV
22 1 1 Negative Positive Humerus Not performed IE IE
MRI Magnetic resonance imaging, w/o without
a Number of detected lesions
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In the remaining 32 patients, results from BMB were
available, and eight patients (25%) had positive findings on
histology. In three of these positive cases, MRI revealed
bone marrow infiltration. In another nine patients with
negative BMB, MRI revealed bone marrow infiltration.
Overall, BMB at the iliac crest was available in 43
patients and was positive in 12 (27.9%) patients. In five
patients with positive BMB, no MRI or direct biopsy was
performed additionally. In seven patients, positive BMB
was confirmed by MRI (n=3), direct biopsy (n=3) or both
(n=1).
The results of the other 31 biopsies were negative for
lymphoma. In seven of these patients, direct biopsy was
positive for lymphoma, which was also confirmed by MRI
in two patients. In nine further patients, MRI showed focal
bone marrow alterations. In the remaining 15 patients, no
direct biopsy or MRI was available. However, in these
patients, as well as in all the other patients, FDG-PET/CT
after the end of treatment normalised without evidence of
focal osseous FDG uptake.
On CT, 32 of 193 (16.6%) lesions were detected without
the PET information (8 osteolysis, 14 sclerosis, 10 mixed).
In 161 lesions (83.4%), only focal increased uptake in the
bone was observed on FDG-PET/CT, without morpholog-
ical alteration of osseous structures on CT images. On a
patient basis, no signs of osseous lymphomatous infiltra-
tion were seen in 28 of 50 patients (56%). Among 35
patients in whom lymphomatous infiltration was proven
either by biopsy or by focal MRI changes, the CT scan was
negative for bone infiltration in 18 (51.4%).
The additional PET/CT information regarding uni- or
multifocal bone involvement upgraded the lymphoma
stage in 21 (42%) patients compared with the combined
information of CT alone and BMB. Seven (14%) patients
had upstaging from an early (stage I/II) to an advanced
stage (stage III/IV). In none of the 50 patients did CT show
any additional bone lesion compared with FDG-PET. All
patients with initial bone involvement on CT, seen as
osteolytic, sclerotic or mixed lesions, had persistent bone
alteration after the end of treatment. The results for each
patient are listed in Tables 4 and 5. Examples are shown in
Figs. 1, 2 and 3.
Table 5. Number of bone lesions, biopsy results and staging with PET/CT and CT alone in 28 NHL patients
No. Lesions on
PET/CTa
Lesions
on CTa
Iliac crest biopsy Direct biopsy Site of biopsy MRI Staging w/o
FDG-PET
Staging with
FDG-PET
1 1 1 Not performed Positive Ileum Not performed IE IE
2 3 0 Positive Not performed Positive IV IV
3 5 4 Not performed Positive Ileum Not performed IV IV
4 2 1 Positive Positive Sacrum Not performed IV IV
5 3 0 Negative Positive Humerus Not performed IIIS IV
6 1 0 Negative Not performed Not performed II IV
7 8 0 Positive Not performed Not performed IV IV
8 2 0 Negative Positive Spine Not performed IIIS IV
9 3 0 Negative Not performed Not performed III IV
10 1 0 Negative Not performed Not performed I IV
11 3 1 Negative Positive Femur Not performed IV IV
12 1 0 Positive Not performed Not performed IV IV
13 1 1 Not performed Positive Sternum Not performed IE IE
14 3 2 Negative Autopsy Lumbar spine Positive IV IV
15 21 0 Not performed Positive Mandible Not performed III IV
16 2 1 Negative Not performed Not performed IV IV
17 1 1 Not performed Positive Humerus Not performed IE IE
18 3 0 Negative Not performed Not performed III IV
19 1 0 Negative Not performed Not performed I IV
20 15 3 Positive Not performed Not performed IV IV
21 3 1 Not performed Positive Femur Not performed IV IV
22 1 0 Negative Not performed Positive II IV
23 10 0 Positive Not performed Not performed IV IV
24 11 2 Positive Positive Skull Positive IV IV
25 15 0 Positive Not performed Positive IV IV
26 1 1 Negative Not performed Positive IV IV
27 6 2 Positive Not performed Not performed IV IV
28 2 0 Negative Not performed Positive III IV
MRI Magnetic resonance imaging, w/o without
a Number of detected lesions
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Discussion
The staging of lymphoma is essential in prognosis and
therapy for patients with NHL and HD. The advanced
stages III and IV correlate significantly with shorter overall
or event-free survival and treatment may have to be
modified accordingly [10]. In HD or NHL, multifocal bone
marrow involvement places the patient in the most
advanced disease stage IV. The European Society for
Medical Oncology (ESMO) minimum clinical recommen-
dations for diagnosis, treatment and follow-up of HD and
NHL recommend a BMB in all patients [11, 12].
In HD, bone marrow infiltration by malignant cells in
BMB occurs in up to 6.5% [13]. Various predictive factors,
including B symptoms, peripheral low cellularity, age over
35 and inguinal involvement, have been established to
predict possible bone marrow infiltration by HD [14].
However, BMB in HD has a low yield and BMI alone does
not define a special high-risk group in which a different
treatment approach is indicated [15]; accordingly, the need
for BMB in all HD patients is questionable [16].
Fig. 2. Images for staging of a
14-year-old boy with HD.
a BMB and bone scintigraphy
were negative for bone involve-
ment. b Coronal maximum in-
tensity projection PET image
shows increased FDG uptake in
cervical and mediastinal lymph
nodes (arrows) and multiple
FDG-avid lesions in the bone
(arrowheads; spine, sacrum).
c Axial CT image at the level of
the sacrum without alteration
of the bony structures (arrows).
d Axial PET/CT image with
increased FDG uptake in the left
sacrum. e Coronal T1-weighted
MR image of the sacrum and
f sagittal T1-weighted MR
image of the lumbar spine
showing multiple hypointense
lesions (arrows), confirming the
diagnosis of lymphomatous
bone involvement
Fig. 3. PET/CT images of a 62-
year-old women with recurrence
of HD. a Axial PET/CT image
showing increased FDG uptake
in an inguinal lymph node
(arrowhead) and the left proxi-
mal femur (arrow). b FDG up-
take was used for planning the
CT-guided percutaneous bone
biopsy. The needle tip (arrow) is
in the lesion. Histology was
positive for lymphomatous
infiltration
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In NHL, bone marrow involvement occurs in 30%–
50% and is more common in indolent histologies [17, 18].
Regarding the focal lymphomatous involvement of bone
marrow, the value of unilateral versus bilateral BMB
remains controversial. It has been shown that bilateral
biopsy of the iliac crest enhances the diagnostic yield of
BMB in HD (22 bilateral BMBs were positive, versus 14
unilateral BMBs) and NHL (237 bilateral BMBs were
positive, versus 24 unilateral BMBs) [9]. These data show
that focal bone marrow infiltrations in NHL and HD can
pass undetected when using unilateral biopsy.
FDG-PET is a whole-body imaging modality with high
sensitivity and specificity for either HD or aggressive
NHL. FDG-PET has been proven to be sensitive in lymph
node staging and identification of organ involvement in
these patients. However, only limited data are available
regarding the impact of FDG-PET in patients with bone
marrow involvement.
In a paper by Nakamoto et al., the authors evaluated the
CT appearance of bone metastases of different tumours
(mainly lung, breast and pancreatic cancers and melano-
ma). They demonstrated that CT images obtained as part of
the PET/CT examination helped to localise bone lesions
exactly. However, CT revealed morphological changes in
only half of the bone lesions. Only 3 of the 179 evaluated
lesions were caused by bone involvement by lymphoma
[19]. Further, FDG-PET is superior to bone scintigraphy in
detecting bone metastases of various malignancies such as
non-small cell lung cancer [20]. Moog et al. reported that
FDG-PET is more sensitive and specific than bone
scintigraphy for identifying bone involvement by lympho-
ma and concluded that FDG-PET can replace bone
scintigraphy in the primary staging of lymphoma [21].
MRI has been proven to be accurate in the staging of
primary bone lymphomas [22, 23]. However, MRI cannot
differentiate viable from non-viable tumour, is somewhat
limited in its anatomical coverage owing to the rather long
imaging time and is therefore currently not used as a
standard staging procedure in patients with lymphoma.
Recent technical developments, however, allow the acqui-
sition of whole-body MRI in rather a short time.
Preliminary data mainly available in paediatric patients
are encouraging, in that they have shown STIR whole-body
MRI to be a sensitive technique for evaluating lympho-
matous involvement of bone marrow as well as non-
marrow sites in a small number of patients [24].
In our patients, FDG-PET had higher diagnostic accu-
racy with regard to bone involvement and staging than
BMB alone, CT alone or the combination of both. Only in
12 of 43 patients with FDG-avid bone lesions was BMB
positive. In contrast, all 18 patients with PET/CT-guided
biopsy of FDG-avid lesions had biopsy-proven lympho-
matous infiltration. However, in the absence of histological
confirmation of all FDG-avid lesions, the sensitivity and
specificity of the PET or the CT cannot be calculated.
FDG-PET upstaged 21 patients (42%) in relation to the
combined information from CT scanning and BMB at the
iliac crest. Seven (14%) patients had upstaging from early
(stages I/II) to advanced stages (stages III/IV), leading to
modification of treatment and prognosis.
Of 193 lesions, 161 (83.41%) were detected only by
FDG-PET. The corresponding lesion on CT was found in
only 16.6% (32 of 193 lesions). These data suggest that
FDG-PET has a much higher sensitivity than CT in the
detection of bone involvement in patients with HD or
aggressive NHL. Also, the administration of intravenous
contrast material does not help to detect more bone lesions
on CT. All of our patients with initial bone involvement on
CT, seen as osteolytic, sclerotic or mixed lesions, had
persistent bone alteration after the end of treatment. Our
data also suggest that neither staging nor evaluation of
therapy response is sufficient with CT alone in patients
with HD or NHL and bone involvement.
Regarding the role of FDG-PET/CT, CT provided
additional information in comparison with FDG-PET in
terms of the correct anatomical localisation of FDG-avid
lesions, but no further lesions were identified. In 18
patients, FDG-avid lesions were biopsied successfully
under CT guidance, with the help of anatomical landmarks
demonstrated on PET/CT. The high accuracy (95%) of
percutaneous bone biopsy relies on cases with morpholog-
ical changes [25]. Only limited experience exists with PET/
CT-guided interventions [26]. The increasing availability
of PET/CT and the detection of FDG-avid lesions without a
morphological correlate will raise the need for PET/CT-
guided interventions.
In conclusion, FDG-PET is superior to CT alone or in
combination with unilateral BMB in detecting bone
marrow involvement in HD and NHL patients and leads
to upstaging in a relevant proportion of patients. In patients
with FDG-avid bone lesions, direct PET/CT-guided bone
biopsy seems to be more accurate than standard BMB in
confirming bone involvement. In the future, the decision to
perform a BMB in patients with HD or NHL and the type
of biopsy procedure should thus be guided by the results of
FDG-PET/CT as the initial staging procedure. In FDG-
negative cases, a BMB is probably still warranted. FDG-
positive bone lesions should be evaluated by direct bone
biopsy or MRI.
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